Therapeutic Potential of Ibuprofen Inhalation for COVID-19 Pneumonia: Report of Two First Cases

German Ambasch1, Esteban Coscia1, Jorge Luis Tambini Diaz1, German David Bueno1, Luis Alberto Arganaras2, Nicolas Martinez Rios2, Daniela Josefina Porta5, Dante Miguel Beltramo3,4 and Nestor Horacio Garcia5*

1Sanatorio Mayo Privado SA, Ciudad de Córdoba, Argentina
2Química Luar SRL, Ciudad de Córdoba, Argentina
3CEPROCOR, Santa María de Punilla, Argentina
4CONICET, Santa María de Punilla, Argentina
5Institute for Research in Health Sciences, Ciudad Universitaria, Argentina

^*Correspondance to: Nestor Horacio Garcia 

 PDF  Full Text DOI: 10.25107/2474-1647.3346

Abstract

No specific and effective antiviral treatment has been approved for COVID-19 so far. Systemic corticosteroid and remdesivir have shown to decrease mortality in COVID-19 patients, but mortality still is elevated. We propose that nebulized hypertonic ibuprofen solution which has bactericidal, virucidal, mucolytic and anti-inflammatory properties to be used for COVID-19 pneumonia and prevent the classical evolution to respiratory failure and mechanical respiration. We report here the first two cases of the COVID-19 pneumonia successfully treated with Nebulized Hypertonic Ibuprofen Solution (NaIHS). Rationale of the treatment is to mitigate the local inflammation with inhaled NIH that stays in the lung and may inhibit proliferation of the virus, inflammation and successfully reverts the hypoxia observed in these clinical cases. Mild adverse events were observed. Larger and further studies are warranted to confirm the result of these cases.

Keywords

Hypertonic ibuprofen solution; Inhalation; Coronavirus disease 2019

Cite the article

Ambasch G, Coscia E, Tambini Diaz JL, Bueno GD, Arganaras LA, Rios NM. Therapeutic Potential of Ibuprofen Inhalation for COVID-19 Pneumonia: Report of Two First Cases. Clin Surg. 2021; 6: 3346..